HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Expert Perspectives on Advances in the Management of C. difficile - Episode 13

C. Difficile Treatment: Bezlotoxumab

The rationale for using bezlotoxumab as treatment for certain patients with C. difficile infections and current limitations that are impacting its use in clinical practice.

EP. 1: C. Difficile Risk Factors and Manifestation
EP. 2: Strains of C. Difficile
EP. 3: Managing Community-Onset C. Difficile
EP. 4: Recurrent C. Difficile
EP. 5: C. Difficile: A Differential Diagnosis
EP. 6: Testing for C. Difficile Infections
EP. 7: Screening for C. Difficile
EP. 8: C. Difficile: Clinical Practice Guidelines and Treatment Options
EP. 9: C. Difficile: Updates to Clinical Practice Guidelines
EP. 10: Selecting Therapy to Treat C. Difficile
EP. 11: C. Difficile Treatment: Fidaxomicin
EP. 12: Choosing Between Vancomycin and Fidaxomicin for C. Difficile Infections
Now Viewing
EP. 13: C. Difficile Treatment: Bezlotoxumab
EP. 14: Preventing/Treating C. Difficile: Unmet Needs
EP. 15: Fecal Microbiota Transplantation for C. Difficile Infections
EP. 16: Emerging Treatment Options for C. Difficile Infections
EP. 17: C. Difficile: Barriers Treating With FMT
EP. 18: Making Strides in the Management of C. Difficile

Related Content:

Expert Perspectives on Advances in the Management of C. difficileC. DIFFICILEGASTROINTESTINAL INFECTIONS
FDA Committee Recommends Approval for Rebyota (RBX2660) to Treat Recurrent C Difficile
Monitoring Patients with C. difficile Infection (CDI) and rCDI
Fecal Microbiota Transplantation (FMT) for Treatment of C. difficile Infection (CDI)